Myeloid-Derived Suppressor Cells

1st Edition, Volume 375 - March 22, 2023
Editors: Carlos Jiménez-Cortegana, Lorenzo Galluzzi
Language: English
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 9 1 2 7 - 5
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 9 1 2 8 - 2

Myeloid-Derived Suppressor Cells, Volume 375 includes comprehensive and detailed reviews on the current advances in myeloid derived suppressor cells, an immature, heterogen… Read more

Purchase options

World Book Day Celebration!

Save up to 30% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Myeloid-Derived Suppressor Cells, Volume 375 includes comprehensive and detailed reviews on the current advances in myeloid derived suppressor cells, an immature, heterogenous cell population from the myeloid lineage that has been extensively described in the last decades due to its potent immunosuppressive activity in a variety of pathologies. Chapters in this new release include Cancer-cell-intrinsic mechanisms regulate myeloid-derived suppressor cells through cytokine networks, Role of myeloid-derived suppressor cells in head and neck cancer, Role of myeloid-derived suppressor cells in breast cancer, Role of myeloid-derived suppressor cells in endometriosis, Role of myeloid-derived suppressor cells in ovarian cancer, Role of myeloid-derived suppressor cells in sarcoma, and more.

Cover image
Title Page
Table of Contents
Copyright
Contributors
Myeloid-derived suppressor cells: Emerging players in cancer and beyond
References
Chapter One: Cancer-cell-intrinsic mechanisms regulate MDSCs through cytokine networks
Abstract
1: Introduction
2: Basic MDSC biology
3: Molecular alterations in tumor cells to promote MDSC accumulation
4: Conclusion
References
Chapter Two: Myeloid-derived suppressor cells in head and neck squamous cell carcinoma
Abstract
1: Introduction
2: A key component of TME: MDSCs
3: Clinical importance of MDSCs
4: Targeting-MDSCs therapy in HNSCC
5: Combination therapy with MDSCs
6: Drug delivery systems of targeting MDSCs
7: Conclusion and perspectives
Conflict of interest
Ethics statement
Authors' contributions
Availability of data and material
References
Chapter Three: Knowing the myeloid-derived suppressor cells: Another enemy of sarcomas patients
Abstract
1: Introduction
2: Sarcoma: Clinical reality and the impact of the TME
3: Myeloid-derived suppressor cells: Subsets and phenotypes
4: MDSCs in sarcomas: The great unknown
5: Targeting MDSCs in sarcomas
6: Conclusions
References
Chapter Four: Role of myeloid-derived suppressor cells during Trypanosoma cruzi infection
Abstract
1: Introduction
2: Importance and markers of myeloid-derived suppressor cells
3: Origin of MDSCs
4: MDSC mechanisms of suppression of the innate and adaptive immune response
5: MDSCs in infections
6: MDSCs in T. cruzi infection
7: MDSCs and potential crosstalk interactions
8: Targeting MDSCs
References
Chapter Five: Emerging avenues linking myeloid-derived suppressor cells to periodontal disease
Abstract
1: Introduction
2: MDSCs in the periodontium
3: MDSCs and periodontal pathogens
4: MDSCs in periodontal disease and associated conditions
5: Conclusion
References
Chapter Six: Myeloid-derived suppressor cells: A new emerging player in endometriosis
Abstract
1: Introduction
2: Origin, phenotype, and functions of MDSCs
3: Frequency of MDSCs in women with endometriosis
4: Putative immunosuppressive functions of MDSCs in endometriosis
5: Other functions of MDSCs in endometriosis
6: Potential therapeutic approach targeting MDSC for endometriosis
7: Conclusion and future perspectives
References

Carlos Jiménez-Cortegana

Carlos Jiménez-Cortegana obtained the degree in Chemistry at University of Seville (Spain) in 2014. In July 2020 he got the PhD in Clinical Research at the same University, belonging to the group headed by Dr. Luis de la Cruz-Merino and Dr. Víctor Sánchez-Margalet. Currently, Carlos is a Postdoctoral Researcher at the Department of Radiation Oncology, Weill Cornell Medical College (New York, USA), in the research group headed by Dr. Lorenzo Galluzzi. From 2021, Carlos has published more than 15 articles in recognized, international journals, some of them in high-impact factor journals, mainly focused on the immunosuppressive role of myeloid-derived suppressor cells in a variety of diseases, including breast cancer, diffuse large B-cell lymphoma, and COVID-19.

Affiliations and expertise

Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Department of Medical Biochemistry, Molecular Biology and Immunology, Faculty of Medicine, University of Seville, Seville, Spain

Lorenzo Galluzzi

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.

Affiliations and expertise

Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health